Hyperandrogenemia as well as the clinical manifestation of hyperandrogenism is one of the typical symptoms of polycystic ovary syndrome. Drospirenone ethinyl estradiol tablets can reduce the level of androgens in women and alleviate the clinical manifestations of hyperandrogenism, and can be used in the treatment of polycystic ovary syndrome in clinical practice. The effect of drospirenone ethinyl estradiol tablets in the treatment of polycystic ovary syndrome is not particularly good, and normal menstrual cycles can be restored after 3-6 months of use in mild polycystic ovary syndrome, while drospirenone ethinyl estradiol tablets are generally effective in the treatment of moderate or severe polycystic ovary syndrome. The effect of drospirenone and ethinyl estradiol tablets in moderate or severe polycystic ovary syndrome is average. In the clinical treatment of polycystic ovaries, the first-line drug is Daying-35, Daying-35 androgen-lowering effect is better than drospirenone ethinyl estradiol tablets, Daying-35 side effects are relatively large, prone to hepatic and renal function, if there is a serious hepatic and renal impairment after 3-6 months of use, the patient should immediately stop using the drug.